List of Azilect drug patents
Azilect is owned by Teva.
Azilect contains Rasagiline Mesylate.
Azilect has a total of 2 drug patents out of which 0 drug patents have expired.
Azilect was authorised for market use on 16 May, 2006.
Azilect is available in tablet;oral dosage forms.
Azilect can be used as treatment of parkinson's disease.
The generics of Azilect are possible to be released after 27 August, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(3 years from now) | |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic